Literature DB >> 9135291

Weaning strategy with inhaled nitric oxide treatment in persistent pulmonary hypertension of the newborn.

H Aly1, R Sahni, J T Wung.   

Abstract

AIM: To determine if infants who had become dependent on inhaled nitric oxide treatment could be successfully weaned off it if FIO2 was increased briefly during withdrawal.
METHODS: Sixteen infants admitted for conditions associated with increased pulmonary vascular resistance responded well to inhaled nitric oxide treatment with a significant increase in PaO2 (maximum inhaled nitric oxide given 25 ppm). Weaning from inhaled nitric oxide in 5 ppm decrements was initiated once the FIO2 requirement was less than 0.5. When patients were stable on 5 ppm of inhaled nitric oxide, the gas was then discontinued. If a patient showed inhaled nitric oxide dependence-that is, oxygen saturation fell by more than 10% or below 85%-inhaled nitric oxide was reinstated at 5 ppm and the patient allowed to stabilise for 30 minutes. At this time, FIO2 was increased by 0.40 and weaning from inhaled nitric oxide was attempted again.
RESULTS: Nine infants were successfully weaned on the first attempt. The seven infants who failed the initial trial were all successfully weaned following the increase in FIO2. After successful weaning, FIO2 was returned to the pre-weaning level in mean 148(SD 51) minutes and inhaled nitric oxide was never reinstated.
CONCLUSION: Infants showing inhaled nitric oxide dependency can be successfully weaned by increasing FIO2 transiently.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135291      PMCID: PMC1720630          DOI: 10.1136/fn.76.2.f118

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  4 in total

1.  Update on PPHN: mechanisms and treatment.

Authors:  Jayasree Nair; Satyan Lakshminrusimha
Journal:  Semin Perinatol       Date:  2014-03       Impact factor: 3.300

Review 2.  Inhaled nitric oxide therapy in neonates and children: reaching a European consensus.

Authors:  Duncan J Macrae; David Field; Jean-Christophe Mercier; Jens Møller; Tom Stiris; Paolo Biban; Paul Cornick; Allan Goldman; Sylvia Göthberg; Lars E Gustafsson; Jürg Hammer; Per-Arne Lönnqvist; Manuel Sanchez-Luna; Gunnar Sedin; Nim Subhedar
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

3.  Inhaled nitric oxide applications in paediatric practice.

Authors:  A Bernasconi; M Beghetti
Journal:  Images Paediatr Cardiol       Date:  2002-01

4.  Persistent pulmonary hypertension of the newborn.

Authors:  Vinay Sharma; Sara Berkelhamer; Satyan Lakshminrusimha
Journal:  Matern Health Neonatol Perinatol       Date:  2015-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.